1. Home
  2. SER vs ACET Comparison

SER vs ACET Comparison

Compare SER & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$1.46

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.17

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SER
ACET
Founded
2017
1947
Country
United States
United States
Employees
13
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4M
69.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SER
ACET
Price
$1.46
$7.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$13.00
$56.00
AVG Volume (30 Days)
65.2K
117.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$134.46
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.45
52 Week High
$7.92
$9.05

Technical Indicators

Market Signals
Indicator
SER
ACET
Relative Strength Index (RSI) 34.91 50.17
Support Level N/A $6.54
Resistance Level $1.86 $8.46
Average True Range (ATR) 0.12 0.46
MACD 0.02 -0.05
Stochastic Oscillator 9.23 37.24

Price Performance

Historical Comparison
SER
ACET

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: